GutCode › Intestinal Permeability Guide
Leaky Gut Is Real — But Probably Not What You've Been Told: The Zonulin Discovery, How LPS Endotoxemia Drives Systemic Inflammation, and the Four Interventions With Actual Human Evidence for Barrier Repair
Updated: June 2026leaky gut · leaky gut syndrome · intestinal permeability · leaky gut science · is leaky gut real · leaky gut evidence · leaky gut research · leaky gut zonulin · zonulin test · zonulin stool test · Fasano zonulin · Alessio Fasano leaky gut · tight junctions gut · tight junction proteins · claudin leaky gut · occludin leaky gut · ZO-1 tight junction · gut barrier · intestinal barrier · epithelial barrier · intestinal epithelium · leaky gut symptoms · leaky gut bloating · leaky gut fatigue · leaky gut skin · leaky gut autoimmune · leaky gut causes · leaky gut gluten · gliadin leaky gut · wheat leaky gut · gluten sensitivity · non-celiac gluten sensitivity · LPS leaky gut · lipopolysaccharide inflammation · LPS endotoxemia · metabolic endotoxemia · LPS insulin resistance · LPS autoimmune · endotoxin leaky gut · inflammatory bowel disease permeability · IBD leaky gut · celiac permeability · type 1 diabetes permeability · autoimmune permeability · leaky gut treatment · leaky gut supplements · leaky gut diet · leaky gut probiotics · leaky gut zinc · zinc carnosine leaky gut · Mahmood 2007 zinc carnosine · zinc carnosine RCT · L-glutamine leaky gut · L-glutamine intestinal barrier · glutamine tight junctions · Akkermansia leaky gut · Akkermansia muciniphila barrier · Akkermansia mucus layer · butyrate leaky gut · butyrate tight junctions · short chain fatty acids barrier · sodium butyrate supplement · colostrum leaky gut · bovine colostrum · leaky gut bone broth · bone broth leaky gut evidence · leaky gut elimination diet · leaky gut heal time · how long to fix leaky gut · lactulose mannitol test · leaky gut blood test · I-FABP test · CLDN3 leaky gut · leaky gut alcohol · NSAID leaky gut · aspirin permeability · leaky gut stress · cortisol tight junctions
The term "leaky gut" became a punchline in mainstream medicine through the early 2000s — dismissed as fringe wellness jargon with no mechanistic basis. That dismissal was premature. In 2000, Alessio Fasano's team at the University of Maryland made a foundational discovery: a protein they named zonulin (now identified as haptoglobin 2 precursor) is the primary physiological regulator of intestinal tight junction permeability in humans. Zonulin is released in response to specific triggers — most prominently gliadin (the protein fraction of gluten) and certain bacterial antigens — and it reversibly opens the tight junctions between intestinal epithelial cells. This is a normal, regulated process. When it becomes dysregulated, the epithelial barrier becomes chronically more permeable than intended.
The correct framing is not "leaky gut causes everything bad" (the wellness industry overclaim) or "leaky gut doesn't exist" (the dismissive medical response). The correct framing is: intestinal permeability is a real, measurable, bidirectional physiological parameter that is elevated in a growing list of conditions including celiac disease, IBD, type 1 diabetes, obesity, non-alcoholic fatty liver disease, and some autoimmune conditions; elevated permeability allows bacterial products (particularly lipopolysaccharide/LPS) to enter the circulation and drive systemic low-grade inflammation; but increased permeability is often a consequence of these conditions rather than necessarily their primary cause; the causal direction is not always clear and varies by condition.
Zonulin
the tight junction regulator — Fasano 2000 (Lancet): discovered that a protein (later identified as haptoglobin 2 precursor and named "zonulin") reversibly opens the tight junctions between intestinal epithelial cells; tight junctions are multi-protein complexes (claudin, occludin, ZO-1, ZO-2, JAM-A) that form a seal between adjacent epithelial cells; normally, molecules must enter the intestinal epithelium through the cell (transcellular transport) where they are subject to enzymatic processing; when tight junctions open (paracellular transport increases), larger molecules can pass between cells without this processing; trigger #1: gliadin — Drago 2006 (Scandinavian Journal of Gastroenterology): gliadin (the immunogenic gluten fraction) triggers CXCR3-dependent zonulin release in ALL humans, not just those with celiac disease; the zonulin response is larger and more sustained in celiac patients, but measurable in everyone; this does not mean gluten is bad for everyone, but it means the "leaky gut from gluten" mechanism applies beyond celiac disease; trigger #2: certain bacterial antigens — gram-negative bacteria express flagellin and other surface proteins that trigger TLR5-mediated zonulin release; this is potentially how dysbiosis promotes increased permeability; trigger #3: stress — psychological stress elevates corticotropin-releasing hormone (CRH), which acts on mast cells in the gut lamina propria to increase permeability; this is the neuro-gut axis mechanism linking psychological stress to gut symptoms
LPS
the systemic inflammation driver — LPS (lipopolysaccharide) is a component of the outer membrane of all gram-negative bacteria; it is one of the most potent activators of the innate immune system; even tiny amounts (picograms) trigger massive TLR4-mediated inflammatory signaling (NFkB activation → TNF-α, IL-1β, IL-6, IL-8); under normal barrier conditions, almost no LPS reaches the portal circulation; when intestinal permeability is increased, small amounts of LPS continuously translocate into the blood → "metabolic endotoxemia" (Cani 2007, Diabetes); Cani 2007 (Diabetes, mouse model): high-fat diet produced a 2-3-fold increase in plasma LPS; this endotoxemia preceded and likely contributed to insulin resistance and obesity; Amar 2008 (Diabetologia): human study — higher fasting plasma LPS associated with future development of obesity and type 2 diabetes; the chronic low-grade inflammation driven by subclinical LPS endotoxemia is mechanistically linked to: insulin resistance (LPS impairs insulin receptor signaling via IKKβ/NFkB pathway), non-alcoholic fatty liver disease (portal LPS activates hepatic Kupffer cells), atherosclerosis (LPS drives endothelial inflammation), and potentially neuroinflammation (via vagal nerve LPS detection + systemic circulation to the brain); measurement: serum LPS-binding protein (LBP) is a clinically available proxy; elevated LBP reflects chronic endotoxin exposure
Zinc-C
the best-evidenced supplement — zinc carnosine (polaprezinc): a chelated compound of zinc and L-carnosine specifically studied for gut barrier protection and repair; Mahmood 2007 (Gut, double-blind RCT): N=100 healthy volunteers; zinc carnosine 75mg (equivalent ~16mg elemental zinc) twice daily vs placebo × 8 weeks, then all subjects received indomethacin (NSAID, known to increase gut permeability as a challenge model); primary outcome: intestinal permeability by lactulose/mannitol ratio; result: zinc carnosine prevented the NSAID-induced increase in permeability vs placebo; zinc carnosine group maintained barrier integrity; Bhattacharyya 2014 (Gastroenterology): zinc carnosine protected against ethanol-induced gut permeability in an additional RCT; mechanism: (1) zinc is essential for claudin and ZO-1 protein synthesis (direct structural component of tight junctions); zinc deficiency → reduced claudin-3, claudin-4, and ZO-1 expression → increased permeability; (2) carnosine independently scavenges reactive oxygen species at the epithelial surface; (3) the zinc-carnosine chelate appears to adhere to the gastric and intestinal mucosa with a longer residence time than free zinc, allowing sustained local delivery; dose used in studies: 75mg zinc carnosine (37.5mg polaprezinc) BID; available OTC in supplement form
Akkermansia
the barrier bacteria — Akkermansia muciniphila: a gram-negative, anaerobic bacterium that lives in and feeds on the intestinal mucus layer; it constitutes 1–4% of the healthy gut microbiome and is consistently reduced in obesity, T2D, IBD, and multiple metabolic conditions; mechanism of barrier protection: Akkermansia produces Amuc_1100 (an outer membrane protein) and short-chain fatty acids from mucin fermentation; Amuc_1100 activates TLR2 on intestinal epithelial cells, upregulating tight junction protein expression (claudin-3, occludin); the bacterium also promotes mucin production, thickening the mucus layer itself; Plovier 2017 (Nature Medicine): Amuc_1100 alone (without live bacteria) was sufficient to improve metabolic parameters in mice, including reduced gut permeability; Depommier 2019 (Nature Medicine, the key human pilot RCT, N=32): pasteurized Akkermansia supplementation (10¹⁰ CFU/day × 3 months) improved metabolic syndrome parameters; more germane: reduced circulating LPS and markers of inflammation; gut permeability markers trended toward improvement; supplementation: live Akkermansia supplements became commercially available 2021–2022 (Pendulum Metabolic Daily, others); pasteurized form also available; prebiotic support: Akkermansia thrives on polyphenols (pomegranate, cranberry, grape seed extract) and mucin precursors; consuming 1–2 cups of berries daily supports Akkermansia abundance
Ready to fix this at the root?
The 30-Day Gut Reset is the full day-by-day protocol — mechanisms, dosed repair steps, a diagnostic chapter, food/swap tables, and a maintenance plan, built from the same research on this page.
Get the Gut Reset → $19
What the Evidence Actually Supports (Ranking by Evidence Quality)
| Intervention | Evidence Level | Mechanism | Practical Use |
|---|
| Zinc carnosine | Strong (2 RCTs in humans) | Zinc = claudin/ZO-1 synthesis cofactor; carnosine = mucosal ROS scavenger; chelate adheres to mucosa for sustained delivery | 75mg BID with meals; well tolerated; primary evidence-based choice for barrier repair |
| Butyrate / sodium butyrate | Moderate (RCTs + extensive mechanistic data) | Butyrate is the primary fuel of colonocytes; activates tight junction gene expression (claudin-1, occludin) via histone deacetylase inhibition; reduces inflammatory cytokines in lamina propria | Sodium butyrate 300–600mg/day; or tributyrin (more bioavailable); or increase dietary fiber → colonic butyrate production |
| L-Glutamine | Moderate (clinical studies, primarily in critical illness) | Glutamine is the preferred fuel of enterocytes (not glucose); required for proliferation of intestinal epithelial cells; supports mucus production; reduces permeability in critically ill patients (Hond 1999) | 5–10g/day; evidence strongest in high-demand states (post-surgery, IBD); evidence in healthy adults is thinner |
| Akkermansia muciniphila | Moderate (1 human RCT + extensive preclinical) | Amuc_1100 protein activates TLR2 → tight junction upregulation; promotes mucus layer thickness | Pasteurized Akkermansia supplement 10¹⁰ CFU/day; or dietary support via polyphenols (pomegranate, cranberry, berries) |
| Specific probiotic strains | Moderate (strain-dependent) | Lactobacillus rhamnosus GG: increases ZO-1 and occludin expression (Madsen 2001, Gastroenterology); Lactobacillus plantarum: reduces permeability in IBS (Saggioro 2004) | Strain specificity matters — LGG and L. plantarum have the strongest barrier data; generic "probiotic" blends may not contain these strains at effective doses |
| Bone broth / collagen peptides | Weak (no RCT for permeability) | Provides glycine (component of collagen that is substrate for mucus glycoproteins) and proline; mechanistically plausible; widely recommended in wellness circles | Reasonable as dietary habit; not evidence-based as a targeted barrier intervention; collagen peptide supplements are more consistent than variable broth preparations |
| Gluten elimination (non-celiac) | Moderate for symptom relief, weak for permeability per se | Removes gliadin → less zonulin release → less tight junction opening; relevant if zonulin is elevated; not justified in all individuals | Relevant in individuals with elevated stool or serum zonulin, or documented gliadin sensitivity; trial of 6–8 weeks with objective re-challenge |
Intestinal Barrier Repair Protocol
Testing: stool zonulin (LabCorp, Genova, Doctor's Data) is the most accessible marker; note: stool zonulin has high variability and limited standardization — it's directionally useful but not definitive; serum LPS-binding protein (LBP) is available at standard labs and provides a systemic marker of endotoxin exposure; intestinal fatty acid binding protein (I-FABP) is a serum marker of acute enterocyte damage, useful in IBD contexts; lactulose/mannitol urine ratio remains the gold standard research test but is not widely available clinically.
First-line intervention (remove triggers first): (1) NSAIDs: even occasional ibuprofen/aspirin use significantly increases permeability; if using NSAIDs regularly, discuss alternatives with physician; (2) Alcohol: dose-dependent permeability increase; even moderate alcohol increases endotoxin translocation; (3) Chronic psychological stress: activate CRH → mast cell degranulation → barrier disruption; stress management is a non-negotiable component of barrier health; (4) Sleep deprivation: chronic short sleep raises cortisol → increased permeability; 7–9 hours is the target; (5) Ultra-processed food: high fat + high sugar diet increases Bacteroidetes/Firmicutes dysbiosis and LPS production; Mediterranean dietary pattern supports barrier integrity.
Active repair stack (evidence-ranked): zinc carnosine 75mg BID with meals (weeks 1–12); sodium butyrate or tributyrin 300–600mg/day (ongoing); L-glutamine 5g/day in warm water on empty stomach (8 weeks); Akkermansia supplement or dietary polyphenol support (ongoing); LGG-containing probiotic daily; increase dietary fiber to 35g/day to support butyrate production; timeline: meaningful reduction in permeability markers typically requires 8–12 weeks of consistent intervention; retest at 12 weeks.
Zinc Carnosine →
Sodium Butyrate →
As an Amazon Associate, GutCode earns from qualifying purchases made through links on this page. This does not affect the price you pay.